Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00616551
Recruitment Status : Completed
First Posted : February 15, 2008
Last Update Posted : October 8, 2008
Information provided by:
Ambrilia Biopharma, Inc.

Brief Summary:
The purpose of this study is to assess the biological safety and efficacy of using the drug, C2L-OCT-01 PR, 30 mg to treat acromegalic patients.

Condition or disease Intervention/treatment Phase
Acromegaly Drug: C2L-OCT-01 PR, 30 mg Drug: Octreotide acetate prolonged release, 30 mg Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 65 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Randomized Study Comparing the Biological Efficacy & Safety of a New Prolonged Release Formulation of Octreotide Acetate, C2L-OCT-01 PR, 30 mg Administered Every 42 Days for 84 Days With Sandostatin LAR 30 mg Administered Every 28 Days for 84 Days to Acromegalic Patients
Study Start Date : April 2007
Primary Completion Date : February 2008
Study Completion Date : February 2008

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: A Drug: C2L-OCT-01 PR, 30 mg
Administered by deep IM injection (gluteus) on days 1 and 42
Active Comparator: B Drug: Octreotide acetate prolonged release, 30 mg
Administered by deep IM (gluteus) on Days 1, 28 and 56
Other Name: Sandostatin LAR, 30 mg

Primary Outcome Measures :
  1. Compare the mean serum concentrations of insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in patients treated with C2L-OCT-01 PR, 30 mg or Sandostatin LAR 30 mg [ Time Frame: Days 1, 28, 42, 56 and 84 ]

Secondary Outcome Measures :
  1. Compare plasma concentrations, efficacy and safety profile of C2L-OCT-01 PR [ Time Frame: 84 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be diagnosed with active acromegaly.
  • If subject is treated with a long acting somatostatin analogue, the treatment must have been unchanged for a period of at least 12 weeks prior to entry.
  • If subject is treated with a 30 mg dose of a depot formulation of a somatostatin analogue, the IGF-1 levels must be normal at entry.
  • If subject is treated with a 20 mg dose of a depot formulation of a somatostatin analogue, any value of IGF-1 is acceptable.
  • If the subject is receiving an immediate release formulation of a somatostatin analogue or a dopamine agonist, the IGF-1 values must be above 10% of the reference range based on gender and age.
  • If the subject is receiving a dopamine agonist, it must be stopped 14 days prior to receiving the study medication.
  • The subject should be able to understand the instructions, provide a written consent and abide by the study restrictions.

Exclusion Criteria:

  • Women of childbearing potential who are not taking adequate contraception or who are pregnant or lactating.
  • Subjects previously treated with a growth hormone receptor antagonist (Pegvisomant) within 12 weeks of study entry.
  • Subjects who have undergone pituitary surgery within 6 months or radiotherapy within 2 years prior to admission into the study
  • Subjects who present some form of intolerance or allergy to the test article or one of its non-active ingredients
  • Subject who have any other condition that alters the growth hormone or IGF-1 levels.
  • Subjects with signs or symptoms related to a tumor compression of the optical chiasm.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00616551

Republican Centre for Medical Rehabilitation and Water-therapy
Minsk, Belarus
Semmelweis Egyetem Általános Orvostudományi
Budapest, Hungary
Institute of Endocrinology "C. I. Parhon" Bucharest
Bucharest, Romania
Institute of Endocrinology, University Clinical Center
Belgrade, Serbia
Fakultná Nemocnica s Poliklinkou Bratislava
Bratislava, Slovakia
V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine
Kiev, Ukraine
Sponsors and Collaborators
Ambrilia Biopharma, Inc.
Study Director: Raphael Naudin, M.D. Ambrilia Biopharma, Inc.

Responsible Party: Bonabes de Rouge, M.D./Senior Executive Vice-President & Chief Scientist Officer, Ambrilia Biopharma, Inc. Identifier: NCT00616551     History of Changes
Other Study ID Numbers: C2L-OCT-01 PR-301
First Posted: February 15, 2008    Key Record Dates
Last Update Posted: October 8, 2008
Last Verified: October 2008

Keywords provided by Ambrilia Biopharma, Inc.:

Additional relevant MeSH terms:
Bone Diseases, Endocrine
Bone Diseases
Musculoskeletal Diseases
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents